Floatz logo

NORAMITRIPTYLINE

Tinnitus

Stanford UniversitySmall moleculePhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Tinnitus cohort.

Asset / SponsorPhaseRating
VERAPAMIL SLOW RELEASE
Stanford University
Phase 4BB
Topamax
Stanford University
Phase 4BB
Paroxetine
University of California, Irvine
Phase 4BB
PROPRANOLOL
Stanford University
Phase 4B
Oxygen
Jay C. Buckey Jr.
Phase 4B

View all 16 →

Same molecule, other indications

NORAMITRIPTYLINE is also rated in:

depressive disorderDormant
BB
Indicative ·
70 / 100
View asset →
Treatment-Refractory DepressionDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →